New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer
| Autor: | Matthias Peipp, Diana Lüftner |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Antibody-drug conjugate medicine.medical_specialty medicine.medical_treatment T-DXd HER2-targeted treatment options antibody-drug conjugate Targeted therapy 03 medical and health sciences 0302 clinical medicine Breast cancer Trastuzumab antibody HER2 Positive Breast Cancer Internal medicine Maternity and Midwifery medicine Review/Übersicht GebFra Science skin and connective tissue diseases 030304 developmental biology DS-8201 0303 health sciences Chemotherapy business.industry Obstetrics and Gynecology metastatic HER2-positive breast cancer medicine.disease Metastatic breast cancer Clinical trial Antikörper-Wirkstoff-Konjugat metastasiertes HER2-positives Mammakarzinom 030220 oncology & carcinogenesis Antikörper HER2-gerichtete Therapieoptionen business medicine.drug |
| Zdroj: | Geburtshilfe und Frauenheilkunde |
| ISSN: | 1438-8804 0016-5751 |
| DOI: | 10.1055/a-1471-4063 |
| Popis: | Despite therapeutic gains in the treatment of HER2-positive (HER2: human epidermal growth factor receptor 2) advanced/metastatic breast cancer, there remains an urgent need for more effective treatment options. At present, there is no definitive approved standard therapy beyond second-line treatment. One of the major challenges is overcoming treatment resistance. Depending on the underlying resistance mechanism, different strategies are being pursued for new innovative treatment concepts in HER2-positive breast cancer. Specifically designed antibodies for targeted therapy are one important focus to successfully meet these challenges. Trastuzumab deruxtecan (T-DXd, DS-8201a), an optimised antibody drug conjugate (ADC) is in clinical trials, showing promising outcomes in patients with advanced, nonoperable or metastatic HER2-positive breast cancer who had already undergone intensive prior treatment. Based on this data, T-DXd has already been approved in the US and Japan for HER2-positive advanced nonoperable and metastatic breast cancer – in the US after at least two prior anti-HER2 targeted treatment lines and in Japan after prior chemotherapy. T-DXd represents successful “antibody engineering”. Since the beginning of the year, T-DXd has also been approved in Europe as monotherapy for inoperable or metastatic HER2-positive breast cancer in patients who are pretreated with at least two anti-HER2 directed therapies. This paper presents strategies for improving treatment options in advanced nonoperable and metastatic HER2-positive breast cancer, with the development of T-DXd as an example. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|